Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MediciNova Obtains Patent on Ibudilast to Treat Drug Dependence
March 21, 2011
- Carna Biosciences to Accelerate Licensing of Its Own Compounds
March 21, 2011
- PIII Results for Halaven to Be Published in The Lancet
March 21, 2011
- Eli Lilly Japan Posts Record-High Sales of ¥134,471 Mil. in 2010
March 14, 2011
- Wholesalers Wither, While Makers Thrive - Effects of New NHI Pricing System?
March 14, 2011
- Sawai to Terminate Negotiations with Kyorin
March 14, 2011
- Japan's Ethical Drug Market Grew 0.2% in 2010: IMS Japan
March 14, 2011
- Ranbaxy to Market Levofloxacin, Ofloxacin in Singapore: Daiichi Sankyo
March 14, 2011
- Takeda Licenses PDE1 Inhibitors from ITI
March 14, 2011
- Japan's Biosimilars Market Has Strong Growth Potential: Mr George of Sandoz
March 14, 2011
- Terumo Acquires CaridianBCT for US$2.6 Bil.
March 14, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- 14-Day Prescription Limit Will Not Apply to Sonias
March 14, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…